TY - JOUR
T1 - Aetiology and incidence of diarrhoea requiring hospitalisation in children under 5 years of age in 28 low-income and middle-income countries
T2 - findings from the Global Pediatric Diarrhea Surveillance network
AU - Cohen, Adam L.
AU - Platts-Mills, James A.
AU - Nakamura, Tomoka
AU - Operario, Darwin J.
AU - Antoni, Sébastien
AU - Mwenda, Jason M.
AU - Weldegebriel, Goitom
AU - Rey-Benito, Gloria
AU - De Oliveira, Lucia H.
AU - Ortiz, Claudia
AU - Daniels, Danni S.
AU - Videbaek, Dovile
AU - Singh, Simarjit
AU - Njambe, Emmanuel
AU - Sharifuzzaman, Mohamed
AU - Grabovac, Varja
AU - Nyambat, Batmunkh
AU - Logronio, Josephine
AU - Armah, George
AU - Dennis, Francis E.
AU - Seheri, Mapaseka L.
AU - Magagula, Nokululeko
AU - Mphahlele, Jeffrey
AU - Fumian, Tulio M.
AU - Maciel, Irene T.A.
AU - Gagliardi Leite, Jose Paulo
AU - Esona, Matthew D.
AU - Bowen, Michael D.
AU - Samoilovich, Elena
AU - Semeiko, Galina
AU - Abraham, Dilip
AU - Giri, Sidhartha
AU - Praharaj, Ira
AU - Kang, Gagandeep
AU - Thomas, Sarah
AU - Bines, Julie
AU - Liu, Na
AU - Kyu, Hmwe H.
AU - Doxey, Matthew
AU - Rogawski Mcquade, Elizabeth T.
AU - Mcmurry, Timothy L.
AU - Liu, Jie
AU - Houpt, Eric R.
AU - Tate, Jacqueline E.
AU - Parashar, Umesh D.
AU - Serhan, Fatima
N1 - Publisher Copyright:
© 2022 Author(s) (or their employer(s)).
PY - 2022/9/5
Y1 - 2022/9/5
N2 - Introduction: Diarrhoea remains a leading cause of child morbidity and mortality. Systematically collected and analysed data on the aetiology of hospitalised diarrhoea in low-income and middle-income countries are needed to prioritise interventions. Methods: We established the Global Pediatric Diarrhea Surveillance network, in which children under 5 years hospitalised with diarrhoea were enrolled at 33 sentinel surveillance hospitals in 28 low-income and middle-income countries. Randomly selected stool specimens were tested by quantitative PCR for 16 causes of diarrhoea. We estimated pathogen-specific attributable burdens of diarrhoeal hospitalisations and deaths. We incorporated country-level incidence to estimate the number of pathogen-specific deaths on a global scale. Results: During 2017-2018, 29 502 diarrhoea hospitalisations were enrolled, of which 5465 were randomly selected and tested. Rotavirus was the leading cause of diarrhoea requiring hospitalisation (attributable fraction (AF) 33.3%; 95% CI 27.7 to 40.3), followed by Shigella (9.7%; 95% CI 7.7 to 11.6), norovirus (6.5%; 95% CI 5.4 to 7.6) and adenovirus 40/41 (5.5%; 95% CI 4.4 to 6.7). Rotavirus was the leading cause of hospitalised diarrhoea in all regions except the Americas, where the leading aetiologies were Shigella (19.2%; 95% CI 11.4 to 28.1) and norovirus (22.2%; 95% CI 17.5 to 27.9) in Central and South America, respectively. The proportion of hospitalisations attributable to rotavirus was approximately 50% lower in sites that had introduced rotavirus vaccine (AF 20.8%; 95% CI 18.0 to 24.1) compared with sites that had not (42.1%; 95% CI 33.2 to 53.4). Globally, we estimated 208 009 annual rotavirus-attributable deaths (95% CI 169 561 to 259 216), 62 853 Shigella-attributable deaths (95% CI 48 656 to 78 805), 36 922 adenovirus 40/41-attributable deaths (95% CI 28 469 to 46 672) and 35 914 norovirus-attributable deaths (95% CI 27 258 to 46 516). Conclusions: Despite the substantial impact of rotavirus vaccine introduction, rotavirus remained the leading cause of paediatric diarrhoea hospitalisations. Improving the efficacy and coverage of rotavirus vaccination and prioritising interventions against Shigella, norovirus and adenovirus could further reduce diarrhoea morbidity and mortality.
AB - Introduction: Diarrhoea remains a leading cause of child morbidity and mortality. Systematically collected and analysed data on the aetiology of hospitalised diarrhoea in low-income and middle-income countries are needed to prioritise interventions. Methods: We established the Global Pediatric Diarrhea Surveillance network, in which children under 5 years hospitalised with diarrhoea were enrolled at 33 sentinel surveillance hospitals in 28 low-income and middle-income countries. Randomly selected stool specimens were tested by quantitative PCR for 16 causes of diarrhoea. We estimated pathogen-specific attributable burdens of diarrhoeal hospitalisations and deaths. We incorporated country-level incidence to estimate the number of pathogen-specific deaths on a global scale. Results: During 2017-2018, 29 502 diarrhoea hospitalisations were enrolled, of which 5465 were randomly selected and tested. Rotavirus was the leading cause of diarrhoea requiring hospitalisation (attributable fraction (AF) 33.3%; 95% CI 27.7 to 40.3), followed by Shigella (9.7%; 95% CI 7.7 to 11.6), norovirus (6.5%; 95% CI 5.4 to 7.6) and adenovirus 40/41 (5.5%; 95% CI 4.4 to 6.7). Rotavirus was the leading cause of hospitalised diarrhoea in all regions except the Americas, where the leading aetiologies were Shigella (19.2%; 95% CI 11.4 to 28.1) and norovirus (22.2%; 95% CI 17.5 to 27.9) in Central and South America, respectively. The proportion of hospitalisations attributable to rotavirus was approximately 50% lower in sites that had introduced rotavirus vaccine (AF 20.8%; 95% CI 18.0 to 24.1) compared with sites that had not (42.1%; 95% CI 33.2 to 53.4). Globally, we estimated 208 009 annual rotavirus-attributable deaths (95% CI 169 561 to 259 216), 62 853 Shigella-attributable deaths (95% CI 48 656 to 78 805), 36 922 adenovirus 40/41-attributable deaths (95% CI 28 469 to 46 672) and 35 914 norovirus-attributable deaths (95% CI 27 258 to 46 516). Conclusions: Despite the substantial impact of rotavirus vaccine introduction, rotavirus remained the leading cause of paediatric diarrhoea hospitalisations. Improving the efficacy and coverage of rotavirus vaccination and prioritising interventions against Shigella, norovirus and adenovirus could further reduce diarrhoea morbidity and mortality.
KW - PCR
KW - child health
KW - epidemiology
KW - infections, diseases, disorders, injuries
KW - public health
UR - http://www.scopus.com/inward/record.url?scp=85138178948&partnerID=8YFLogxK
U2 - 10.1136/bmjgh-2022-009548
DO - 10.1136/bmjgh-2022-009548
M3 - Article
C2 - 36660904
AN - SCOPUS:85138178948
SN - 2059-7908
VL - 7
JO - BMJ Global Health
JF - BMJ Global Health
IS - 9
M1 - e009548
ER -